Related Experiment Video

Updated: Sep 20, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials

Panu Wetwittayakhlang1,2, Alex Al Khoury3, Gustavo Drügg Hahn1,4

  • 1Division of Gastroenterology, McGill University Health Center, Montreal, QC H3G 1A4, Canada.

Journal of Clinical Medicine
|June 10, 2022
PubMed

Insights

Fistulizing Crohn's disease (FCD) management is complex, with limited treatment options. Emerging therapies show promise for improving fistula healing rates in patients with Crohn's disease.

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease
  • Surgical Gastroenterology

Background:

  • Fistulizing Crohn's disease (FCD) affects up to 30% of Crohn's disease (CD) patients, causing significant disability.
  • Current treatment strategies for FCD are limited by sparse randomized clinical trial (RCT) evidence, leading to practice variations.
  • Anti-tumor necrosis factor (anti-TNF) therapy has the strongest evidence but achieves long-term fistula healing in only 30-50% of patients.

Purpose of the Study:

  • To review current and emerging therapeutic modalities for managing fistulizing Crohn's disease.
  • To provide guidance for managing FCD beyond the limitations of existing RCT data.
  • To summarize evidence on novel treatments to improve fistula healing outcomes.

Main Methods:

  • Comprehensive literature review of existing studies on FCD therapies.
  • Analysis of data from RCTs, real-world clinical studies, and expert opinions.
  • Evaluation of emerging therapeutic options, including biologics, drug monitoring, surgical techniques, and stem cell therapy.

Main Results:

  • Anti-tumor necrosis factor (anti-TNF) therapy is the most established treatment, with moderate long-term efficacy.
  • Newer modalities like advanced biologics, therapeutic drug monitoring, novel surgical approaches, and mesenchymal stem cell therapy show potential for improved outcomes.
  • Significant variation exists in clinical practice due to limited high-quality evidence.

Conclusions:

  • Optimal FCD management requires a multidisciplinary, combined medical and surgical approach.
  • Emerging therapies offer new hope for improving fistula healing rates in FCD.
  • Further research and high-quality clinical trials are needed to optimize FCD treatment strategies.

Keywords:
Crohn’s diseaseanti-TNFbiologicfistulizinginternal fistulaperianal fistulastem cells therapy

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
226
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
433
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243